Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
This study has been completed.
Study NCT00166296 Information provided by Germans Trias i Pujol Hospital
First Received: September 9, 2005 Last Updated: March 25, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depressive Disorder.
Hepatitis C, Chronic
Additional conditions recognized in this trial
Depression
Depressive Disorder
Depressive Disorder, Major
Hepatitis
Hepatitis C
Hepatitis, Chronic
More general conditions related to this trial
Behavioral Symptoms
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Mental Disorders
Mood Disorders
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Escitalopram
Placebo
Additional drug interventions recognized in this trial
Citalopram
Dexetimide
Interferons
Peginterferon alfa-2a
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Anti-Infective Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antineoplastic Agents
Antiparkinson Agents
Antiviral Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Germans Trias i Pujol Hospital
Hoffmann-La Roche
H. Lundbeck A/S
Back to top of Main Content
